Transposition of cardiovascular outcome trial effects to the real-world population of patients with type 2 diabetes.

ABSTRACT:

Background

Transferring results obtained in cardiovascular outcome trials (CVOTs) to the real-world setting is challenging. We herein transposed CVOT results to the population of patients with type 2 diabetes (T2D) seen in routine clinical practice and who may receive the medications tested in CVOTs.

Methods

We implemented the post-stratification approach based on aggregate data of CVOTs and individual data of a target population of diabetic outpatients. We used stratum-specific estimates available from CVOTs to calculate expected effect size for the target population by weighting the average of the stratum-specific treatment effects according to proportions of a given characteristic in the target population. Data are presented as hazard ratio (HR) and 95% confidence interva

SUBMITTER: Sciannameo V 

PROVIDER: S-EPMC8112047 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature